Results 271 to 280 of about 151,694 (306)
Some of the next articles are maybe not open access.
Hematology/Oncology Clinics of North America, 1996
Myelosuppression is the most common toxicity associated with the administration of dose-intensive cytotoxic chemotherapy. The basic understanding of neutrophil biology and the physiology of chemotherapy-induced neutropenia has advanced tremendously in the past 2 decades.
S K, Kim, G D, Demetri
openaire +2 more sources
Myelosuppression is the most common toxicity associated with the administration of dose-intensive cytotoxic chemotherapy. The basic understanding of neutrophil biology and the physiology of chemotherapy-induced neutropenia has advanced tremendously in the past 2 decades.
S K, Kim, G D, Demetri
openaire +2 more sources
Annals of Internal Medicine, 1986
Excerpt To the editor: In the September issue, Wallis and colleagues (1) describe the association of polyarthritis and neutropenia associated with circulating large granular lymphocytes.
openaire +2 more sources
Excerpt To the editor: In the September issue, Wallis and colleagues (1) describe the association of polyarthritis and neutropenia associated with circulating large granular lymphocytes.
openaire +2 more sources
Seminars in Hematology, 2002
Cyclic neutropenia is a rare hematologic disorder, characterized by repetitive episodes of fever, mouth ulcers, and infections attributable to recurrent severe neutropenia. Fluctuations in blood cells are due to oscillatory production of cells by the bone marrow.
David C, Dale +2 more
openaire +2 more sources
Cyclic neutropenia is a rare hematologic disorder, characterized by repetitive episodes of fever, mouth ulcers, and infections attributable to recurrent severe neutropenia. Fluctuations in blood cells are due to oscillatory production of cells by the bone marrow.
David C, Dale +2 more
openaire +2 more sources
International Journal of Antimicrobial Agents, 2000
Newer treatment strategies for the management of febrile neutropenic patients are being developed. These include: (a) hospital based oral therapy; (b) early discharge after initial stabilization in-hospital, and (c) out-patient therapy. All strategies are likely to be more successful in patients with short-lived neutropenia (< or = 7 days) than in ...
openaire +2 more sources
Newer treatment strategies for the management of febrile neutropenic patients are being developed. These include: (a) hospital based oral therapy; (b) early discharge after initial stabilization in-hospital, and (c) out-patient therapy. All strategies are likely to be more successful in patients with short-lived neutropenia (< or = 7 days) than in ...
openaire +2 more sources
Archives of disease in childhood - Education & practice edition, 2008
Townshend, J. +5 more
openaire +5 more sources
Townshend, J. +5 more
openaire +5 more sources